News

Pharmabiz12h
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation
Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation: Estero, Florida Thursday, June 26, 2025, 18:00 Hrs [IST] ...
AZ Central3d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - AZCentral | The ...
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation Written by aspire biopharma holdings inc.
Detroit Free Press3d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Detroit Free Press
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation Written by aspire biopharma holdings inc.
Miami Herald2d
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Miami Herald
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ACCESS Newswire Updated June 24, 2025 8:41 AM ...